儿童和青少年急性偏头痛家庭式耳迷走神经刺激早期显示良好前景
Home-based auricular vagus nerve stimulation shows early promise for kids and teens with migraines
一项针对7至18岁儿童和青少年的前瞻性单臂探索性研究显示,家庭式耳迷走神经刺激(taVNS)治疗急性偏头痛安全可行,72次治疗中仅出现轻微局部皮肤反应,无严重不良事件。研究期间,疼痛评分下降,2小时无药痛缓解率36.11%,平均发作时间及每月偏头痛天数减少。尽管为开放标签单臂试验,未设对照组,但结果为设计更大规模随机对照试验奠定了基础。
As clinicians and researchers, we often see how heavily migraine attacks weigh on children and adolescents, yet non-pharmacological, child-friendly treatment options remain strikingly scarce. For years, our team at Nanfang Hospital and collaborating institutes have been looking into ways to bridge this gap.
Recently, our team set out to explore whether a gentle, at-home wearable technology—transcutaneous auricular vagus nerve stimulation (taVNS)—could offer a safe and feasible way to help young patients manage acute migraine episodes.
Targeting the vagus nerve through the ear
To understand how this works, you first need to know about the vagus nerve. It is one of the most extensive cranial nerves in our body, acting as a major highway between the brain and the internal organs. It plays a key role in the parasympathetic nervous system to regulate involuntary functions such as heart rate, digestion, and physiological homeostasis.
During a migraine attack, central pain processing and autonomic regulation can become disrupted. Transcutaneous auricular vagus nerve stimulation (taVNS) delivers mild electrical pulses to the auricular branch of the vagus nerve—specifically at the left cymba conchae of the outer ear, a region rich in vagal innervation. This non-invasive stimulation is thought to modulate autonomic activity and activate central pain-inhibitory pathways in the brain.
Encouraging signals in pain relief and safety
In our prospective, single-arm exploratory study recently published in Neuromodulation: Technology at the Neural Interface, we evaluated 11 pediatric and adolescent patients (ages 7 to 18) who self-administered 30-minute taVNS sessions at home over a 4-week period, tracking a total of 72 treated attacks.
First and foremost, the approach proved to be highly feasible and well-tolerated. Out of 72 treatment sessions, we recorded only two mild, transient local skin reactions at the stimulation site, with no serious adverse events reported.
Furthermore, visual analog scale (VAS) pain scores showed a consistent downward trajectory within attacks, and medication-free 2-hour pain freedom was observed in 36.11% of the treated episodes. When comparing the 4-week intervention period to retrospective baseline data, we also noted reductions in average attack duration and monthly migraine days.
Scientific caution and paving the way for controlled trials
These encouraging results build directly upon our team's earlier, step-by-step groundwork in non-invasive neuromodulation. Previously, we established a rigorous methodological and technical framework for auricular vagus nerve stimulation through a published study protocol on closed-loop taVNS for stroke motor recovery, while simultaneously capturing direct early clinical signals in a case report on taVNS for pediatric chronic migraine. Combining that technical rigor with real-world pediatric observations paved a solid foundation for this prospective, single-arm exploratory study.
Even with this solid groundwork in place, we believe it is crucial as scientists to interpret the findings of this early-stage trial with a high degree of caution. Because our study was designed as an open-label, single-arm trial without a control group, we cannot definitively attribute the observed pain relief or longitudinal changes solely to the taVNS intervention. Pediatric migraines can feature high variability and natural remission, and psychological expectancy or placebo effects always play a role.
Additionally, our exploratory analysis of heart rate variability (HRV) did not yield statistically significant changes after correcting for multiple testing, indicating that HRV cannot currently serve as a reliable biomarker for treatment response.
Despite these limitations, our findings provide a vital stepping stone. They demonstrate that home-based neuromodulation can be safely administered by children and families in a real-world setting. More importantly, they validate the operational framework needed to design our next major milestone: an adequately powered, sham-controlled randomized trial. By establishing safety and feasibility now, we hope to move closer to offering young migraine sufferers a validated, nondrug therapeutic tool for the future.
This story is part of Science X Dialog, where researchers can report findings from their published research articles. Visit this page for information about Science X Dialog and how to participate.
Publication details
Siqi Weng et al., Home-Based Transcutaneous Auricular Vagus Nerve Stimulation for Acute Migraine in Children and Adolescents: A Prospective Single-Arm Exploratory Study with Heart Rate Variability Assessment, Neuromodulation: Technology at the Neural Interface (2026). DOI: 10.1016/j.neurom.2026.10.002
Journal information: Frontiers in Psychiatry
Who's behind this story?
Lisa Lock
BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Dr. Jane Xiao is a cognitive neuroscientist, founder of ZenoWell, and founder of the Vagus Nerve Community. She earned her Ph.D. (Cognitive Neuroscience) in 2019 at the Chinese University of Hong Kong. She translates complex neuroscience into everyday health solutions, supporting the five pillars of longevity—sleep, relaxation, nutrition, movement, and connection. Her research focuses on neuromodulation—specifically, how transcutaneous auricular vagus nerve stimulation (taVNS) can regulate the autonomic nervous system to improve sleep, stress recovery, and overall well-being.
Citation: Home-based auricular vagus nerve stimulation shows early promise for kids and teens with migraines (2026, November 18) retrieved 18 November 2026 from https://medicalxpress.com/news/2026-11-home-based-auricular-vagus-nerve.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com